Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

Go To Global Site
Welcome to UCB in the United States

U.S. Public Policy Inspired by Patients


UCB is committed to the discovery, development, and delivery of differentiated solutions that provide measurable value to patients— improving their lives now and in the future. We’re focused on addressing unmet needs and creating sustainable solutions for patients and society. As such, we are dedicated to the continued evolution of a public policy environment that recognizes and rewards innovation, encourages value-based care, and promotes affordable access to medicines for patients. UCB’s patient value ambition creates the foundation of our approach to public policy, which aims to:

  • Deliver unique outcomes that help specific patients achieve their goals;
  • Provide patients the best individual experience; and
  • Ensure access to all those who need these solutions in a way which is viable for patients, society, and UCB.


This approach guides our engagement in the healthcare ecosystem and the public policy arena.

 

Innovation

Innovation

UCB is committed to the development of transformative solutions that treat, modify, or cure severe diseases for patients with unmet medical needs. Therefore, we support policy approaches that:
 

  • Ensure the U.S. Food and Drug Administration (FDA) remains true to its mission1 of protecting patient safety, and preserve the U.S. system of track and trace;
  • Incorporate the patient voice in treatment development and regulatory decision making;
  • Support patient-preferred, innovative clinical trial designs;
  • Accelerate innovation through incentives for continued investment and the use of real-world evidence (RWE)2  as a supplement to randomized clinical trials (RCT) in regulatory decision making;
  • Increase the ability of payers to partner with innovators earlier in the drug development process; and
  • Advance meaningful protections for innovator intellectual property.

Value-Based Care

Value-Based-Care

UCB is committed to delivering value-based care for patients through policy approaches that:

  • Remove policy barriers to collaboration among patients, payers, providers, caregivers, and policymakers in developing value- and outcomes-based payment models;
  • Support informed, shared healthcare decision-making between patients and physicians;
  • Promote an environment that rewards value and encourages continued medical innovation;
  • Incorporate the patient voice and real word evidence (RWE) in healthcare quality measures and value assessments; and
  • Foster a value assessment environment that recognizes multiple frameworks and definitions of value.

Affordable Access

Affordable-Access

UCB is committed to promoting affordable access to care for patients through policy approaches that:

  • Ensure patients have access to a range of health plan options that meet their individual needs and offer robust protections like transparent, reliable formularies and affordable out-of-pocket costs;
  • Remove impediments to providers’ ability to prescribe the most appropriate therapy to patients, including step-edits and restrictive formularies, while also reducing patient out-of-pocket expenses; and
  • Permit assistance for patients who cannot afford needed medicines.

 

DOWNLOAD OUR POLICY POSITIONS

 

 

1 https://www.fda.gov/about-fda/what-we-do

2 UCB considers RWE to be any clinical and/or economic findings with respect to disease burden, treatment utilization and outcomes, comparative effectiveness, etc. that analyzes real-world data. Real-world data includes, but is not limited to, medical and pharmacy administrative claims, electronic medical/health records, product/disease registries, and patient-reported outcomes collected through various channels. Methods and analytical approaches (including artificial intelligence) to real-world data collection and RWE generation can vary but acknowledge that RWE must be appropriately executed based on proposed research objectives and be fit for purpose.

U.S. CLINICAL TRIALS
U.S. INNOVATION
UCB IN THE U.S.

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)